Paul Wallace joined Mission Therapeutics in 2015 as Chief Business Officer.
Dr Wallace brings over 20 years of international business development experience, having worked across this role with several drug discovery companies. Most recently, he was EVP and Head of Business Development for Medivir AB during its transition into a profitable pharmaceutical company. He led the execution of multiple transactions with major pharmaceutical companies, resulting in the launch of two drugs, including the hepatitis C protease inhibitor, Olysio®. Prior to his roles in business development, Dr Wallace had a career in pharmaceutical research developing antibody therapeutics for oncology indications. He also carried out post-doctoral studies in biochemistry at the University of Cambridge.
Dr Wallace holds a PhD in biochemistry from the University of Cambridge, UK.